These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 1835879

  • 1. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
    [No Abstract] [Full Text] [Related]

  • 2. The role of interleukin-2 in the biotherapy of cancer.
    Parkinson DR.
    Oncol Nurs Forum; 1989 Sep; 16(6 Suppl):16-20. PubMed ID: 2687810
    [Abstract] [Full Text] [Related]

  • 3. Clinical applications of IL-2.
    Sznol M, Parkinson DR.
    Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
    [Abstract] [Full Text] [Related]

  • 4. Relapse after successful treatment with immunotherapy: lessons for the future.
    Fisher RI.
    Cancer J Sci Am; 1998 Jun; 4(2):78-9. PubMed ID: 9532407
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A, Savona S, Gafney E, Penichet KO, Lin BY, Levitt D, Ahmed T, Arlin ZA, Baskind P, Needleman D.
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-2, killer cells and cancer therapy: an overview.
    Parkinson DR, Lotzová E.
    Nat Immun Cell Growth Regul; 1990 Oct; 9(4):237-41. PubMed ID: 2215512
    [No Abstract] [Full Text] [Related]

  • 7. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC.
    Cancer J Sci Am; 1998 Oct; 4(2):86-93. PubMed ID: 9532410
    [Abstract] [Full Text] [Related]

  • 8. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F, Escudier B.
    J Biol Response Mod; 1990 Dec 15; 9(6):546-55. PubMed ID: 2074441
    [Abstract] [Full Text] [Related]

  • 10. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 11. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW, Fuchs HA.
    J Rheumatol; 1994 Apr 15; 21(4):752-3. PubMed ID: 8035405
    [Abstract] [Full Text] [Related]

  • 12. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P, Vitté-Mony I, Farace F, Stancou R, Triebel F, Escudier B, Hercend T, Bertoglio J.
    Eur Cytokine Netw; 1990 Apr 15; 1(3):185-8. PubMed ID: 2129800
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T.
    J Biol Response Mod; 1990 Apr 15; 9(2):167-77. PubMed ID: 1971303
    [Abstract] [Full Text] [Related]

  • 16. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC, Belldegrun A, Figlin RA.
    Semin Oncol; 1995 Feb 15; 22(1):74-80. PubMed ID: 7855622
    [No Abstract] [Full Text] [Related]

  • 17. Interleukin-2.
    Med Lett Drugs Ther; 1987 Sep 25; 29(749):88-9. PubMed ID: 3306301
    [No Abstract] [Full Text] [Related]

  • 18. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA, Pierce WC, Belldegrun A.
    Semin Oncol; 1993 Dec 25; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract] [Full Text] [Related]

  • 19. Recombinant interleukin-2 and the quest for FDA approval.
    Tami JA.
    Clin Pharm; 1991 Feb 25; 10(2):141-2. PubMed ID: 2009733
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of renal cell carcinoma and melanoma patients with immune RNA.
    Pilch YH.
    J Exp Pathol; 1987 Feb 25; 3(4):501-14. PubMed ID: 2457665
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.